Wang Junnan, Yan Youyou, Song Dandan, Liu Bin
Department of Cardiology, Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, China.
Department of Clinical Laboratory, Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, China.
Biomed Res Int. 2016;2016:4285942. doi: 10.1155/2016/4285942. Epub 2016 Dec 5.
Coronary collateral circulation (CCC), an alternative blood supply for ischemic myocardium, improves survival rates among patients with coronary artery disease (CAD). However, there remains a lack of biomarkers to discriminate between patients with poor or good CCC. In this study, we aimed to observe the relationship between plasma microRNA-146a (miR-146a) levels and the coronary collateral circulation (CCC). Additionally, we aimed to explore whether the plasma miR-146a level could serve as a blood-based biomarker for CCC in patients with CAD. We measured the plasma levels of vascular endothelial growth factor A (VEGF-A) and miR-146a in patients with CCC by ELISA and real-time PCR, respectively, according to the Rentrop grades. The results showed that the plasma miR-146a level is significantly increased in CAD patients with good CCC and significantly decreased in those with poor CCC. In contrast, although VEGFA expression in patients followed a similar trend as the CCC, the differences between the groups were not statistically significant. There was a positive correlation between plasma miR-146a levels and the Rentrop grading. In addition, receiver operator characteristic analysis showed that miR-146a could be a potent biomarker for identifying patients with poor CCC.
冠状动脉侧支循环（CCC）是缺血心肌的一种替代性血液供应，可提高冠状动脉疾病（CAD）患者的生存率。然而，目前仍缺乏能够区分CCC良好或不良患者的生物标志物。在本研究中，我们旨在观察血浆微小RNA-146a（miR-146a）水平与冠状动脉侧支循环（CCC）之间的关系。此外，我们旨在探讨血浆miR-146a水平是否可作为CAD患者CCC的一种基于血液的生物标志物。我们根据Rentrop分级，分别采用酶联免疫吸附测定法（ELISA）和实时聚合酶链反应（real-time PCR）测量了CCC患者血浆中血管内皮生长因子A（VEGF-A）和miR-146a的水平。结果显示，CCC良好的CAD患者血浆miR-146a水平显著升高，而CCC不良的患者则显著降低。相比之下，尽管患者体内VEGFA的表达趋势与CCC相似，但各组之间的差异无统计学意义。血浆miR-146a水平与Rentrop分级呈正相关。此外，受试者工作特征分析表明，miR-146a可能是识别CCC不良患者的有效生物标志物。
